Drug Profile
Rabies immune globulin - Kamada
Alternative Names: Anti-rabies IgG - Kamada; HRIG - Kamada; Human rabies immunoglobulin - Kamada; KamRAB; KEDRABLatest Information Update: 19 May 2023
Price :
$50
*
At a glance
- Originator Unknown
- Developer Kamada; Kedrion; OncBioMune; Pan American Health Organization; Valneva
- Class Antivirals; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Rabies
Most Recent Events
- 15 Mar 2023 Launched for Rabies (Prevention) in Australia (IM)
- 31 Dec 2022 Rabies immune globulin is available for Rabies (Prevention) in Poland, Brazil, Argentina, Bosnia-Herzegovina (IM) and is being marketed without registration as of December 2022
- 02 Jun 2021 Efficacy data from a US paediatric clinical trial in Rabies released by Kedrion and Kamada